HIV-1 Subtypes and Primary Antiretroviral Resistance Mutations in Antiretroviral Therapy Naive HIV-1 Infected Individuals in Turkey

DOI Web Site PubMed 1 Citations
  • Sayan M.
    Clinical Laboratory, PCR Unit, Faculty of Medicine, University of Kocaeli
  • Willke A.
    Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, University of Kocaeli
  • Ozgunes N.
    Department of Infectious Diseases and Clinical Microbiology, Goztepe Educational and Research Hospital, University of Istanbul Medeniyet
  • Sargın F.
    Department of Infectious Diseases and Clinical Microbiology, Goztepe Educational and Research Hospital, University of Istanbul Medeniyet

Search this article

Abstract

In this study, we determined the subtype distribution and the primary drug-resistant mutations in HIV-1 strains isolated from antiretroviral therapy (ART)-naive patients in Turkey. The study included 117 newly diagnosed HIV-1 positive Turkish patients. HIV-1 subtypes and circulating recombinant forms (CRFs) were identified by phylogenetic analysis (neighbor-joining method), and drug-resistant mutations were analyzed according to the 2009 World Health Organization list of surveillance drug-resistant mutations. Subtype CRFs (CRF 02_AG, CRF 01_AE, CRF 12_BF and CRF 03_AB; 47%, 55/117) and B (33.3%, 39/117) were identified as the most common occurring HIV-1 subtypes in Turkey. The patients had primary antiretroviral resistance mutations to nucleos(t)ide reverse transcriptase (RT) inhibitors (NRTIs) (M41L, T215C, T215D, and K219Q), non-nucleoside RT inhibitors (NNRTIs; K103N), and protease inhibitors (PIs; I47V, G73S). The prevalence of overall primary antiretroviral resistance was 7.6% (9/117) in HIV-1 patients from Turkey and drug-resistant rate for NRTIs, NNRTIs, and PIs were 4.2% (5/117), 1.7% (2/117), and 1.7% (2/117), respectively. In this study, various CRFs of HIV-1 were determined, for the first time, in Turkey. The prevalence of HIV-1 primary drug-resistant mutations in ART-naive patients suggested that resistance testing should be incorporated as an integral part of HIV management, and the choice of a first-line therapy regime should be guided by the results of genotypic resistance in Turkey.

Journal

  • Japanese Journal of Infectious Diseases

    Japanese Journal of Infectious Diseases 66 (4), 306-311, 2013

    National Institute of Infectious Diseases, Japanese Journal of Infectious Diseases Editorial Committee

Citations (1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top